PharmaCorp Rx Inc.
PharmaCorp Rx Inc. operates retail pharmacies under the PharmaChoice name in Canada. It offers prescription drug and custom compounding specialization services; weight loss and lifestyle management solutions, including health and wellness products; and convenience and confectionary products. The company was incorporated in 2021 and is headquartered in Saskatoon, Canada.
PharmaCorp Rx Inc. (PCRX) - Net Assets
Latest net assets as of September 2025: CA$30.21 Million CAD
Based on the latest financial reports, PharmaCorp Rx Inc. (PCRX) has net assets worth CA$30.21 Million CAD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$39.71 Million) and total liabilities (CA$9.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$30.21 Million |
| % of Total Assets | 76.08% |
| Annual Growth Rate | 215.32% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 553.85 |
PharmaCorp Rx Inc. - Net Assets Trend (2021–2024)
This chart illustrates how PharmaCorp Rx Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PharmaCorp Rx Inc. (2021–2024)
The table below shows the annual net assets of PharmaCorp Rx Inc. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$30.57 Million | +1243.97% |
| 2023-12-31 | CA$2.27 Million | -16.29% |
| 2022-12-31 | CA$2.72 Million | +178.89% |
| 2021-12-31 | CA$974.18K | -- |
Equity Component Analysis
This analysis shows how different components contribute to PharmaCorp Rx Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 200033800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$32.37 Million | 106.68% |
| Total Equity | CA$30.34 Million | 100.00% |
PharmaCorp Rx Inc. Competitors by Market Cap
The table below lists competitors of PharmaCorp Rx Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RATH Aktiengesellschaft
VI:RAT
|
$31.04 Million |
|
PT Eagle High Plantations Tbk
F:7B7
|
$31.04 Million |
|
JCH Systems Inc
KQ:033320
|
$31.04 Million |
|
Sakar Healthcare Limited
NSE:SAKAR
|
$31.05 Million |
|
Cyberfuels Holding Company Inc.
PINK:CBRF
|
$31.02 Million |
|
Tplex Co. Ltd
KQ:081150
|
$31.02 Million |
|
Ilji Technology Co. Ltd
KQ:019540
|
$31.01 Million |
|
Sinil Pharmaceutical Co. Ltd
KQ:012790
|
$31.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PharmaCorp Rx Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,274,326 to 30,343,781, a change of 28,069,455 (1234.2%).
- Net loss of 1,050,935 reduced equity.
- New share issuances of 27,327,975 increased equity.
- Other factors increased equity by 1,792,415.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-1.05 Million | -3.46% |
| Share Issuances | CA$27.33 Million | +90.06% |
| Other Changes | CA$1.79 Million | +5.91% |
| Total Change | CA$- | 1234.19% |
Book Value vs Market Value Analysis
This analysis compares PharmaCorp Rx Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.66x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 17.66x to 1.66x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CA$0.02 | CA$0.43 | x |
| 2022-12-31 | CA$0.07 | CA$0.43 | x |
| 2023-12-31 | CA$0.06 | CA$0.43 | x |
| 2024-12-31 | CA$0.26 | CA$0.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PharmaCorp Rx Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.14%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.16x
- Recent ROE (-3.46%) is above the historical average (-14.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -19.03% | 0.00% | 0.00x | 1.01x | CA$-788.78K |
| 2023 | -20.68% | 0.00% | 0.00x | 1.02x | CA$-697.86K |
| 2024 | -3.46% | -18.14% | 0.16x | 1.16x | CA$-4.09 Million |
Industry Comparison
This section compares PharmaCorp Rx Inc.'s net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $3,008,438
- Average return on equity (ROE) among peers: -426.51%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PharmaCorp Rx Inc. (PCRX) | CA$30.21 Million | -19.03% | 0.31x | $31.02 Million |
| ShinyBud Corp (SNYB) | $3.01 Million | -426.51% | 6.53x | $280.55K |